Bridgemarq Real Estate Services Inc. ("Bridgemarq" or the "Company") today released its third quarter consolidated financial results and announced a monthly dividend to holders of the Company's ...

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression ...